Welcome to our dedicated page for Balchem SEC filings (Ticker: BCPC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Balchem’s microencapsulated choline and specialty gases make its disclosures more complex than a typical chemical company. Revenue shifts between Human Nutrition & Health and Animal Nutrition & Health, raw-material pricing, and R&D on encapsulation technology are buried deep in the 10-K. Tracking executive stock sales across four business segments shouldn’t require dissecting hundreds of pages.
Stock Titan’s AI reads every Balchem SEC filing the moment it hits EDGAR and serves you a plain-English brief. Whether you need the Balchem insider trading Form 4 transactions, a Balchem quarterly earnings report 10-Q filing, or the latest 8-K material events explained, our platform highlights what moves margins, flags new patents, and decodes footnotes. Real-time alerts surface Balchem Form 4 insider transactions in real time and map them against upcoming earnings so you can act quickly.
Use the annual report 10-K simplified view to compare segment profit trends, scan the proxy statement executive compensation table to see how leadership is rewarded for nutritional innovation, or explore the Balchem earnings report filing analysis for quarter-over-quarter volume changes. From understanding Balchem SEC documents with AI to monitoring Balchem executive stock transactions Form 4, every filing is linked, summarized, and searchable. Stop scrolling through PDFs and start focusing on decisions—our AI-powered summaries, real-time updates, and complete coverage of 10-K, 10-Q, 8-K, Form 4, and proxy materials put the right details at your fingertips.
Balchem Corp. (BCPC) EVP, Chief Legal Officer & Secretary Hatsuki Miyata filed a Form 4 reporting an internal share withholding associated with restricted-stock vesting.
- Transaction: On 07/25/2025, 483 common shares were automatically withheld (code “F”) to satisfy tax obligations at a reported price of $148.82, representing roughly $72 k of tax value.
- Post-transaction ownership: 6,189 shares held directly; 462 shares held indirectly through the company 401(k) plan.
- Interpretation: Code F is a non-discretionary event; no open-market buying or selling occurred, so investment signal is neutral.
No derivative securities were involved and there is no impact on Balchem’s capital structure.
Balchem Corporation held its Annual Meeting of Shareholders on June 18, 2025, where three significant matters were put to vote:
- Board Elections: Three Class 1 directors were elected to serve until 2028: - Theodore L. Harris (24.9M votes for) - Monica Vicente (26.4M votes for) - Matthew Wineinger (26.1M votes for)
- Auditor Appointment: Shareholders strongly approved RSM US LLP as the independent registered public accounting firm for FY2025, with 28.8 million votes in favor (98.2% approval)
- Executive Compensation: The say-on-pay vote passed with 25.4 million votes in favor (93.6% of votes cast), showing strong shareholder support for the company's executive compensation practices
All proposals received substantial shareholder approval, indicating strong governance alignment and shareholder satisfaction with the company's direction.
FAQ
What is the current stock price of Balchem (BCPC)?
What is the market cap of Balchem (BCPC)?
